Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Companies Sue Government Over New OTC Online Purchase Regulation

This article was originally published in PharmAsia News

Executive Summary

Two major online marketing companies in Japan, Kenko.com and Wellnet filed May 25 a lawsuit against the government over online purchase regulations for over-the-counter drugs. A ministerial ordinance from the Ministry of Health, Labor and Welfare requires face-to-face transactions for OTC drugs categorized as class 1 and 2. A pharmacist explanation is required for class 1 drugs, and an explanation from a pharmacist or a registered seller is required for class 2 drugs. Japanese online marketers consider the regulation an actual ban on the online purchase of the drugs. The two companies claim that the government's decision to ban Internet sales went beyond its jurisdiction. (Click here for more - Japanese language

You may also be interested in...



Russia Prepares $10 COVID-19 Vaccine For International Launch

Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.

Galapagos Sells CRO To Selvita For €31.2m

The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.

EU Clinical Trial Portal Requires Rethink On Balancing Business Interests & Transparency

In the first of a two-part article on transparency provisions for the new EU clinical trial portal, the Pink Sheet reports on aspects that sponsors must consider to protect commercially confidential information in their clinical trial applications. The second article will look at the approach taken by Merck and discuss outstanding hot topics in relation to transparency and CTIS.

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel